NeoGenomics, Inc. $NEO Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC trimmed its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 23.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,815,949 shares of the medical research company’s stock after selling 546,100 shares during the period. Segall Bryant & Hamill LLC owned about 1.40% of NeoGenomics worth $14,019,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in NEO. Aster Capital Management DIFC Ltd increased its stake in shares of NeoGenomics by 42.5% in the third quarter. Aster Capital Management DIFC Ltd now owns 3,341 shares of the medical research company’s stock worth $26,000 after buying an additional 997 shares during the last quarter. Moody National Bank Trust Division increased its position in shares of NeoGenomics by 1.4% in the 3rd quarter. Moody National Bank Trust Division now owns 90,476 shares of the medical research company’s stock worth $698,000 after purchasing an additional 1,227 shares during the last quarter. Amalgamated Bank raised its stake in shares of NeoGenomics by 3.4% in the 3rd quarter. Amalgamated Bank now owns 37,965 shares of the medical research company’s stock valued at $293,000 after purchasing an additional 1,255 shares in the last quarter. Moors & Cabot Inc. lifted its position in shares of NeoGenomics by 20.0% during the second quarter. Moors & Cabot Inc. now owns 12,000 shares of the medical research company’s stock worth $88,000 after purchasing an additional 2,000 shares during the last quarter. Finally, State of Tennessee Department of Treasury lifted its position in shares of NeoGenomics by 3.6% during the second quarter. State of Tennessee Department of Treasury now owns 58,082 shares of the medical research company’s stock worth $425,000 after purchasing an additional 2,039 shares during the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

Insider Transactions at NeoGenomics

In other NeoGenomics news, COO Warren Stone sold 22,128 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $12.50, for a total value of $276,600.00. Following the completion of the transaction, the chief operating officer owned 121,631 shares in the company, valued at approximately $1,520,387.50. This represents a 15.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.40% of the stock is owned by insiders.

NeoGenomics Trading Up 0.4%

NASDAQ:NEO opened at $9.54 on Wednesday. NeoGenomics, Inc. has a 12-month low of $4.72 and a 12-month high of $13.74. The firm has a market capitalization of $1.24 billion, a P/E ratio of -11.36 and a beta of 1.62. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.26 and a quick ratio of 3.94. The business has a 50 day simple moving average of $11.76 and a 200 day simple moving average of $10.39.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, February 17th. The medical research company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. NeoGenomics had a negative return on equity of 3.10% and a negative net margin of 14.85%.The firm had revenue of $190.17 million for the quarter, compared to analyst estimates of $188.25 million. During the same period last year, the company earned $0.04 earnings per share. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. Equities research analysts predict that NeoGenomics, Inc. will post -0.2 EPS for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on NEO shares. UBS Group reissued a “hold” rating on shares of NeoGenomics in a report on Wednesday, February 18th. Needham & Company LLC lifted their target price on NeoGenomics from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Zacks Research lowered NeoGenomics from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 20th. Weiss Ratings restated a “sell (d-)” rating on shares of NeoGenomics in a research note on Monday, December 29th. Finally, Benchmark reaffirmed a “hold” rating on shares of NeoGenomics in a report on Wednesday, February 18th. Five analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, NeoGenomics presently has a consensus rating of “Hold” and an average price target of $11.86.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.